FCS | Jotup

Florida Cancer Specialists & Research Institute Expands Radiation Oncology Services in Central Florida

Retrieved on:

Friday, September 1, 2023

Cancer, Partnership, Health, Physician, Patient, FCS, Nursing, Medical imaging, Central Florida, MD

FORT MYERS, Fla., Sept. 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) Is pleased to announce that Central Florida Cancer Care Center/Radiation Oncology Consultants, PA has joined the statewide practice, effective September 1, 2023.

Key Points:

FORT MYERS, Fla., Sept. 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) Is pleased to announce that Central Florida Cancer Care Center/Radiation Oncology Consultants, PA has joined the statewide practice, effective September 1, 2023.
Nathan H. Walcker , FCS Chief Executive Officer, said, "Across Florida, we continue to add and enhance services so that patients can easily access world-class cancer treatment close to home.
This partnership will provide many benefits for the Central Florida community, our patients and our clinic teams."
"Inhouse capabilities such as extensive next-generation testing and access to cutting-edge clinical trials will enhance our ability to develop personalized treatment plans that target each patient's unique cancer."

Hyzon Motors Inc., Announces Second Quarter 2023 Financial and Operational Results

Retrieved on:

Tuesday, August 8, 2023

ROCHESTER, N.Y., Aug. 8, 2023 /PRNewswire/ -- Hyzon Motors Inc. (NASDAQ: HYZN) ("Hyzon" or the "Company"), a high-power hydrogen fuel cell technology developer and global supplier of zero-emission heavy-duty fuel cell electric vehicles ("FCEVs"), today announced its second quarter 2023 financial and operational results.

Key Points:

ROCHESTER, N.Y., Aug. 8, 2023 /PRNewswire/ -- Hyzon Motors Inc. (NASDAQ: HYZN) ("Hyzon" or the "Company"), a high-power hydrogen fuel cell technology developer and global supplier of zero-emission heavy-duty fuel cell electric vehicles ("FCEVs"), today announced its second quarter 2023 financial and operational results.
By the end of the second quarter, Hyzon had deployed seven vehicles under commercial agreements to customers in 2023; three additional vehicles were deployed subsequent to the quarter end.
This followed successful completion and factory acceptance testing of the initial three single-stack 200kW FCS during the first quarter of 2023.
The Hyzon management team will host a conference call to discuss its second quarter 2023 financial results on Tuesday, August 8, 2023, at 8:30 a.m. Eastern Time.

Florida Cancer Specialists & Research Institute Announces Senior Leadership Team Appointment

Retrieved on:

Tuesday, August 1, 2023

Operation, LDD, Doctor of Pharmacy, Pharmacy, ION, MBA, Group purchasing organization, Magellan Health, Acquisition, Patient, Corporation, National Directorate of Intelligence and Prevention Services, GPO, FCS, Environment, Management, Nursing

FORT MYERS, Fla. , Aug. 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce the promotion of a member of its executive leadership team, Paul Chadwick, to Chief Value and Procurement Officer.

Key Points:

FORT MYERS, Fla. , Aug. 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce the promotion of a member of its executive leadership team, Paul Chadwick, to Chief Value and Procurement Officer.
"Paul has been instrumental in efforts to strategically streamline procurement tactics for the practice to date," remarked FCS Chief Executive Officer Nathan H. Walcker.
Paul joined FCS in 2019 with nearly 10 years of experience in both clinical and community oncology industry leadership roles.
"He also shares a passion for advancing precision oncology to serve our patients, which is central to our mission."

Study Confirms Effectiveness of Trilaciclib for Treatment of Patients with Extensive-Stage Small Cell Lung Cancer Co-authored by Florida Cancer Specialists & Research Institute Physicians and Senior Leaders

Retrieved on:

Monday, July 31, 2023

FORT MYERS, Fla., July 31, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physicians and senior leaders are co-authors of a study that confirms the effectiveness of trilaciclib for the treatment of adult patients with Extensive-Stage Small Cell Lung Cancer. Trilaciclib is the first FDA-approved therapy in its class to help protect bone marrow cells from damage caused by chemotherapy.

Key Points:

FORT MYERS, Fla., July 31, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physicians and senior leaders are co-authors of a study that confirms the effectiveness of trilaciclib for the treatment of adult patients with Extensive-Stage Small Cell Lung Cancer.
Trilaciclib is the first FDA-approved therapy in its class to help protect bone marrow cells from damage caused by chemotherapy.
The abstract, Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy, was recently published in the journal, Advances in Therapy.
"Our study evaluated real-world outcomes of patients using data from published and unpublished studies of trilaciclib and comparable non-trilaciclib-treated patients," said Dr. Hart.

Institute for Value-Based Medicine® from The American Journal of Managed Care® hosts ‘Genomics, Real-World Evidence, and Phase 1 Innovations in a Community Oncology Practice’ event in Tampa

Retrieved on:

Thursday, July 27, 2023

Real-World Evidence, University of Florida Cancer and Genetics Research Complex, IVBM, Partnership, AOCNP, MSN, Nursing, The American Journal of Managed Care, AJMC, Research, EDT, American Journal, Physician, FCS, Genomics

The in-person event, Genomics, Real-World Evidence, and Phase 1 Innovations in a Community Oncology Practice, will be held in partnership with Florida Cancer Specialists & Research Institute at Hilton Downtown Tampa from 5-9 p.m. EDT.

Key Points:

The in-person event, Genomics, Real-World Evidence, and Phase 1 Innovations in a Community Oncology Practice, will be held in partnership with Florida Cancer Specialists & Research Institute at Hilton Downtown Tampa from 5-9 p.m. EDT.
“We are excited to partner with Florida Cancer Specialists & Research Institute (FCS) for this transformative event,” said Gil Hernandez, vice president of AJMC.
“Together, we will leverage the power of real-world evidence and discuss strategies to provide personalized care within community oncology practices.
With genomics, real-world evidence, and phase 1 innovations at the forefront, attendees will delve into the latest advancements and transformative breakthroughs in oncology.

Tampa General Hospital Opens Infusion Center at the TGH Cancer Institute's State-of-the-Art Satellite Location

Retrieved on:

Wednesday, July 19, 2023

TAMPA, Fla. , July 19, 2023 /PRNewswire/ -- In an endeavor to expand cancer care for the rapidly growing communities of south Hillsborough County, Tampa General Hospital (TGH) opened a state-of-the-art, 26-bay Infusion Center in the TGH Cancer Institute's Brandon location. A ribbon-cutting ceremony was held on July 19. Additionally, a Radiation Oncology Center will open at the Brandon location, 10740 Palm River Road, this fall.

Key Points:

TAMPA, Fla. , July 19, 2023 /PRNewswire/ -- In an endeavor to expand cancer care for the rapidly growing communities of south Hillsborough County, Tampa General Hospital (TGH) opened a state-of-the-art, 26-bay Infusion Center in the TGH Cancer Institute's Brandon location.
"Our new TGH Cancer Institute location allows us to expand our reach and provide greater access to our community."
The TGH Cancer Institute satellite location in Brandon is part of Tampa General's $550 million master facility plan, the largest in the hospital's almost 100-year history.
The addition to the TGH Cancer Institute's Infusion Center will offer seven more chemotherapy areas for the treatment of cancer.

East-West Shrine Bowl Announces Top 1,000 Candidates for 2024 College Football All-Star Game

Retrieved on:

Monday, July 17, 2023

TAMPA, Fla., July 17, 2023 /PRNewswire-PRWeb/ -- The East-West Shrine Bowl, the nation's oldest college football all-star game, has released its annual Shrine Bowl 1,000 today of top eligible collegiate stars for the upcoming 2024 game.

Key Points:

The nation's oldest college football all-star game, the East-West Shrine Bowl, has released its list of top eligible collegiate stars for the upcoming 2024 game.
TAMPA, Fla., July 17, 2023 /PRNewswire-PRWeb/ -- The East-West Shrine Bowl , the nation's oldest college football all-star game, has released its annual Shrine Bowl 1,000 today of top eligible collegiate stars for the upcoming 2024 game.
"The Shrine Bowl 1,000 serves as the first look at who may be at the 2024 East-West Shrine Bowl," said Eric Galko, Director of Football Operations and Player Personnel for the Shrine Bowl.
Eric Galko, Director of Football Operations and Player Personnel for the Shrine Bowl, is available for interviews.

HYZON MOTORS INC. ANNOUNCES MILESTONE IN PRODUCTION OF 200KW SINGLE-STACK FUEL CELL SYSTEM

Retrieved on:

Monday, July 10, 2023

First Nine B-Sample Fuel Cell Systems Successfully Assembled and Tested; On Track to Declare C-Sample in late 2023 and Begin Production in 2024

Key Points:

First Nine B-Sample Fuel Cell Systems Successfully Assembled and Tested; On Track to Declare C-Sample in late 2023 and Begin Production in 2024
ROCHESTER, N.Y., July 10, 2023 Hyzon Motors Inc. (Hyzon) (NASDAQ: HYZN), a high-power hydrogen fuel cell technology developer and global supplier of zero-emission heavy-duty fuel cell electric vehicles (FCEVs), today announced the successful completion and factory acceptance testing of the first nine single-stack 200kW Fuel Cell System (FCS) B-samples at its production and innovation center in Bolingbrook, IL.
By achieving this milestone, Hyzon remains on track to declare Start of Production (SOP) and commercialization of its innovative FCS in 2024.
The successful completion of testing of Hyzon's nine 200kW FCS B-samples in the first half of 2023 demonstrates consistent progress toward commercial production.
This achievement follows the commissioning of Hyzon's proprietary, automated roll-to-roll Membrane Electrode Assembly (MEA) production line including in-line inspection and the installation of its single cell and fully automated fuel cell stack manufacturing lines.

AFFOA Partners with National Family and Consumer Sciences Education Leaders

Retrieved on:

Wednesday, June 28, 2023

Workforce, Partnership, Home economics, Curriculum, Textile industry, Advanced Functional Fabrics of America, Mountain West Conference, American Association of Family and Consumer Sciences, Thumb, STEM, Textile, FCS, Education, EWD, Female, Nursing, Management, AFFOA, Family

CAMBRIDGE, Mass. , June 28, 2023 /PRNewswire/ -- The Advanced Functional Fabrics of America (AFFOA) Manufacturing Innovation Institute is partnering with the leadership of Family and Consumer Sciences (FCS) programs across the United States to ensure that the FCS textile curriculum is recognized as a valuable entry point to STEM-based careers in advanced functional fabrics.

Key Points:

AFFOA and FCS curriculum is recognized as a valuable entry point to STEM-based careers in advanced functional fabrics.
Forming a partnership with AFFOA means Family & Consumer Sciences Education once again has their thumb on the heartbeat of this industry today and for the future.
Family and Consumer Sciences programs across the country are a valuable, yet in AFFOA's opinion, an underutilized conduit to advanced fabric careers.
AFFOA is looking forward over the coming years to produce a variety of research-based materials and new Textile based STEM experiences for Family and Consumer Science students nationwide.

Florida Cancer Specialists & Research Institute and IDEOlogy Health Announce Partnership to Launch Customized Multi-Channel Medical Education for its Providers

Retrieved on:

Friday, June 23, 2023

Genetic testing, Partnership, IDEO, Sound, Ideology, Patient, Physician, FCS, Pharmaceutical industry, Mobile phone, Nursing

FORT MYERS, Fla. and AUSTIN, Texas, June 23, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) a leader in value-based oncology care, announced today a partnership with IDEOlogy Health to serve as the exclusive provider of multi-channel medical education for the providers within the statewide practice.

Key Points:

FORT MYERS, Fla. and AUSTIN, Texas, June 23, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) a leader in value-based oncology care, announced today a partnership with IDEOlogy Health to serve as the exclusive provider of multi-channel medical education for the providers within the statewide practice.
FCS will have access to IDEO's suite of services including live events & digital platforms, IDEO Talks, and Sound Bites.
For nearly 40 years, FCS has been providing cancer care to patients in the communities in which they live, inclusive of groundbreaking genetic testing and clinical trials.
"We are honored to have the opportunity to build customized multi-channel education for FCS and its providers," remarked Mike Gramling, IDEOlogy Health CEO.